Editas Medicine (EDIT) FY 2025 Conference September 03, 2025 08:00 AM ET Company ParticipantsDana Sheehan - Associate Director - Corporate CommunicationsGilmore O’Neill - Director, President & CEOLinda Burkly - EVP & Chief Scientific OfficerAlec Stranahan - VP - Equity ResearchBill Maughan - MD, Equity Research - BiotechnologyJonathan Miller - MD - Biotech & Pharma Equity ResearchSoumit Roy - MD - HealthcareTony Deng - VP - Biotechnology Equity ResearchConference Call ParticipantsJack Allen - Senior Researc ...

Editas Medicine (EDIT) FY 2025 Conference September 03, 2025 08:00 AM ET Speaker0Our lead development candidate, Edit 401. This webinar is being recorded and can be accessed in the future through this same link or through the Investors section of the company's website. After our prepared remarks, we will open the call to Q&A. To ask a question, please click the raise hand feature in the webinar portal. As a reminder, various remarks that we make during this presentation about the company's future expectatio ...

AnaptysBio (ANAB) 2025 Conference September 03, 2025 08:00 AM ET Company ParticipantsPrakhar Agrawal - Managing DirectorDaniel Faga - President & CEOPrakhar AgrawalAll right. Hello, everyone. Good morning. Welcome to day one of the CANTER Global Healthcare Conference. For the first session today, we have AnaptysBio. My name is Prakhara Gurwal. I'm a biotech analyst on CANTER. Joining us from AnaptysBio, we have Dan Faga, President and Chief Executive Officer. Dan, thank you for coming to us.Daniel FagaGood ...

REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences: Baird 2025 Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 1:25 p.m. Eastern Daylight Time / 10:25 a.m. Pacific Daylight TimeH.C. Wainwright 27th Annual Global Investment Conference in New York, NY on Wednesday, September 10, 2025, at 11:00 a.m. Eastern Daylight Time / 8:00 a. ...

Media ReleaseCOPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient settingAdverse event profile and efficacy were consistent with previously reported studies in R/R DLBCL patients Data also demonstrated 64.3% overall response rate w ...

WVE-006: RNA editing for AATD Positive RestorAATion-2 clinical data update Investor presentation September 3, 2025 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing ...

Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1). FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age- ...

PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second line (2L) settingRonde-cel is Lyell’s next-generation, dual-targeting CD19/CD20 CAR T-cell therapy designed to deliver improved complete response rates and longer duration of responses over currently approved CD19 CAR T-cell therapiesSteering Committee of distinguished lymphoma experts establis ...

OS Therapies to Participate in Upcoming Investor Conferences in September 2025September 03, 2025 7:40 AM EDT | Source: OS TherapiesNew York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will participate in the upcoming investor conferences:Cantor Global Healthcare Conference 2025 being held September 3-5, ...

Company Overview - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases [1][3] - The company aims to transform care for patients with immuno-inflammatory diseases through a portfolio of first-in-class oral medicines [2][3] Leadership Change - Brian Adams has been appointed as Chief Legal Officer and Corporate Secretary, succeeding Ellen Chiniara, who is retiring [1][2] - Mr. Adams brings nearly two decades of experience in the life sciences sector, having held senior legal roles at various biopharmaceutical companies [2] Strategic Focus - Kymera is pioneering the field of targeted protein degradation (TPD) to develop innovative therapies that address health problems not accessible with conventional treatments [3] - The company has advanced its first degrader into clinical trials for immunological diseases and is building a pipeline of oral small molecule degraders [3]